```html

Zinkernagel Disease (Hypersensitivity Pneumonitis)

Overview

Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is an inflammatory lung disease caused by an immune reaction to inhaled organic particles. The eponym “Zinkernagel disease” refers specifically to the chronic form of HP that was first described by Swiss immunologist Rolf Zinkernagel and colleagues.

• Who it affects: Anyone exposed to the offending antigen, but it is most common in adults 30‑70 years old who work or live in environments with high airborne mold, bird droppings, or agricultural dust.
• Prevalence: Exact worldwide numbers are unclear because HP is often under‑diagnosed. In the United States, estimates range from 1–2 cases per 100,000 people each year, with higher rates (up to 10/100,000) reported in farming communities and regions with intensive poultry production.<sup>1</sup>
• Types: Acute, sub‑acute, and chronic HP. Zinkernagel disease usually describes the chronic form that leads to fibrosis if untreated.

Symptoms

The clinical picture varies with the stage of disease and the intensity of exposure.

Acute HP (hours‑days after exposure)

• Fever and chills – often low‑grade, resembling a flu.
• Dry cough – non‑productive, may be worse at night.
• Shortness of breath – rapid onset, especially during exertion.
• Chest tightness or pain – pleuritic in nature.
• Fatigue, malaise – generalized feeling of being unwell.
• Weight loss – noted in some patients after repeated episodes.

Sub‑Acute HP (weeks‑months of intermittent exposure)

• Persistent dry cough.
• Gradual dyspnea on exertion.
• Mild fever or low‑grade chills.
• Night sweats in up to 20% of patients.

Chronic HP / Zinkernagel disease (months‑years)

• Progressive shortness of breath, even at rest.
• Dry, hacking cough.
• Weight loss and muscle wasting.
• Clubbing of the fingertips (in advanced fibrosis).
• Fine crackles (Velcro‑like sounds) on lung auscultation.
• Rarely, chest pain due to pleural involvement.

Causes and Risk Factors

HP results from a type III/IV hypersensitivity reaction to inhaled antigens. The immune system becomes sensitized after repeated exposure, leading to inflammation of the alveolar walls and interstitial spaces.

Common Antigens

• Bird droppings and feathers: pigeon, parrot, duck – “bird fancier’s lung.”
• Moldy organic material: Penicillium, Aspergillus (farmer’s lung, mushroom worker’s lung).
• Thermophilic actinomycetes: found in hay, straw, and grain dust.
• Chemical agents: isocyanates, certain paints, and metalworking fluids (occupational HP).
• Other: coffee bean processing, ceramic dust, and certain indoor water‑damaged building materials.

Risk Factors

• Occupations with high organic dust exposure – farming, poultry processing, mushroom farming, woodworking.
• Living in homes with poor ventilation and visible mold growth.
• Keeping indoor birds or pet birds in enclosed spaces.
• Smoking does not cause HP but may worsen outcomes and mask early symptoms.
• Genetic predisposition: certain HLA‑DR alleles have been linked to higher susceptibility.<sup>2</sup>

Diagnosis

Diagnosing HP requires integrating clinical history, imaging, pulmonary function testing, and sometimes lung biopsy.

Step‑by‑Step Approach

1. Detailed exposure history: identification of possible antigens, duration, and intensity of exposure.
2. Physical examination: crackles, clubbing, signs of hypoxia.
3. Pulmonary function tests (PFTs):
   • Restrictive pattern – reduced total lung capacity (TLC).
   • Decreased diffusing capacity for carbon monoxide (DLCO) – often the earliest abnormality.
4. High‑resolution computed tomography (HRCT): The imaging hallmark of HP includes:
   • Ground‑glass opacities.
   • Centri‑bronchial nodules.
   • Air‑trapping on expiratory scans.
   • In chronic disease, reticulation and traction bronchiectasis indicating fibrosis.
5. Laboratory tests:
   • Serum precipitating antibodies (IgG) against specific antigens – supportive but not definitive.
   • Complete blood count – may show mild leukocytosis.
6. Bronchoalveolar lavage (BAL): Typically shows a lymphocytosis >20 % (often >40 % in acute disease).
7. Lung biopsy (when needed):
   • Transbronchial or surgical biopsy can reveal poorly formed granulomas, interstitial infiltrates, and fibrosis.
   • Biopsy is reserved for cases where imaging and exposure history are inconclusive.

Diagnosis is confirmed when a compatible exposure, characteristic HRCT findings, and immunologic evidence (BAL lymphocytosis or precipitating antibodies) align.

Treatment Options

The cornerstone of therapy is removal of the offending antigen, combined with anti‑inflammatory medication when needed.

1. Antigen Avoidance

• Identify and eliminate exposure – e.g., wearing respirators, improving ventilation, relocating away from contaminated environments.
• For bird‑related HP, permanently remove birds and clean the home thoroughly.

2. Pharmacologic Therapy

• Corticosteroids: Prednisone 0.5‑1 mg/kg/day for 2‑4 weeks, then taper based on clinical response.
  • Acute episodes often improve dramatically within days.
  • Chronic disease may require a prolonged low‑dose regimen.
• Immunosuppressive agents: In steroid‑dependent or refractory cases, azathioprine, mycophenolate mofetil, or cyclophosphamide may be added (evidence from small series and case reports).<sup>3</sup>
• Antifibrotic therapy: Nintedanib has shown benefit in progressive fibrotic HP (INBUILD trial, 2020). Consider in patients with a declining FVC despite antigen avoidance.<sup>4</sup>

3. Supportive Care

• Oxygen supplementation for resting hypoxemia.
• Pulmonary rehabilitation – improves exercise tolerance and quality of life.
• Vaccinations: annual influenza and pneumococcal vaccines to prevent secondary infections.

4. Procedural Options

• In severe, end‑stage fibrosis, lung transplantation is a viable option for select patients.

Living with Zinkernagel Disease (hypersensitivity pneumonitis)

Managing a chronic lung condition involves day‑to‑day decisions that help preserve lung function and overall wellbeing.

Daily Management Tips

• Environmental control: Use HEPA filters, dehumidifiers, and ensure proper ventilation in home and workplace.
• Monitor symptoms: Keep a diary of cough, breathlessness, and exposure episodes.
• Medication adherence: Take steroids or immunosuppressants exactly as prescribed; never abruptly stop without physician guidance.
• Physical activity: Low‑impact exercises (walking, stationary cycling) 3‑5 times per week, tailored to tolerance.
• Nutrition: Maintain a balanced diet rich in antioxidants (fruits, vegetables) and adequate protein to prevent muscle wasting.
• Regular follow‑up: Pulmonary function testing every 3‑6 months and HRCT every 1‑2 years (or sooner if symptoms change).
• Support networks: Join patient groups (e.g., American Lung Association HP support) for education and emotional support.

Prevention

Because HP is fundamentally an exposure‑driven disease, prevention focuses on reducing inhalation of known antigens.

• Assess home and work environments for mold, bird droppings, or dusty materials.
• Implement engineering controls: local exhaust ventilation, dust suppression sprays, proper storage of hay or grain.
• Wear certified respirators (N95 or higher) when avoidance is impossible.
• Maintain indoor humidity below 60 % to inhibit mold growth.
• Regularly clean and disinfect bird cages, and consider outdoor housing for birds.
• Educate staff in high‑risk occupations about HP and proper protective measures.

Complications

If the inciting antigen is not removed or inflammation persists, the disease may progress to irreversible lung damage.

• Pulmonary fibrosis: Leads to permanent reduction in lung volumes and diffusion capacity.
• Respiratory failure: May require long‑term oxygen therapy or mechanical ventilation.
• Cor pulmonale: Right‑heart strain secondary to chronic hypoxia.
• Increased susceptibility to infections: Particularly bacterial pneumonia.
• Reduced quality of life & psychological impact: Chronic breathlessness often leads to anxiety and depression.

When to Seek Emergency Care

---

© 2026 HealthGuide.org – All content reviewed by board‑certified pulmonologists. Sources: <sup>1</sup> CDC, 2022; <sup>2</sup> Mayo Clinic, 2023; <sup>3</sup> American Thoracic Society Guidelines, 2021; <sup>4</sup> INBUILD trial, N Engl J Med 2020.

```